Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines

Immune checkpoint inhibitors are increasingly used in combination with chemotherapy for the treatment of non-small cell lung cancer, yet the success of combination therapies is relatively limited. Thus, more detailed insight regarding the tumor molecular markers that may affect the responsiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Saar, Marika, Jaal, Jana, Meltsov, Alvin, Laasfeld, Tõnis, Lust, Helen, Kasvandik, Sergo, Lavogina, Darja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221650/
https://www.ncbi.nlm.nih.gov/pubmed/37242727
http://dx.doi.org/10.3390/pharmaceutics15051485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221650/
https://www.ncbi.nlm.nih.gov/pubmed/37242727
http://dx.doi.org/10.3390/pharmaceutics15051485

Ejemplares similares